Security key
114082209
Ernexa Therapeutics Inc. - Common Stock (ERNA)
CUSIP: 114082209
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 1,166,181
- Total 13F shares
- 390,079
- Share change
- -19,127
- Total reported value
- $712,390
- Price per share
- $1.83
- Number of holders
- 19
- Value change
- -$47,643
- Number of buys
- 5
- Number of sells
- 6
Report period
Q2 2024
Institutions
19
Top holders
10
ERNA full security history
Newer quarter: Q3 2024
Previous quarter: Q1 2024
Ernexa Therapeutics Inc. SEC filings
Ernexa Therapeutics Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 114082209
Recent filing periods:
Top shareholders of ERNA - Ernexa Therapeutics Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| Cypress Point Wealth Management, LLC |
13F
|
Company |
8.1%
|
94,375
|
$226,500 | — | 31 Mar 2024 | |
| Naviter Wealth, LLC |
13F
|
Company |
6.8%
|
78,796
|
$189,110 | — | 31 Mar 2024 | |
| Sippican Capital Advisors |
13F
|
Company |
6.2%
|
72,800
|
$174,720 | — | 31 Mar 2024 | |
| Corient Private Wealth LLC |
13F
|
Company |
4.3%
|
50,398
|
$120,451 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
2.2%
|
26,099
|
$62,638 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.9%
|
22,488
|
$53,782 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
1.3%
|
15,619
|
$37,486 | — | 31 Mar 2024 | |
| Avidian Wealth Enterprises, LLC |
13F
|
Company |
1.3%
|
14,798
|
$35,515 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.87%
|
10,091
|
$24,117 | — | 31 Mar 2024 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.86%
|
10,083
|
$24,000 | — | 31 Mar 2024 | |
| BALDWIN WEALTH PARTNERS LLC/MA |
13F
|
Company |
0.73%
|
8,544
|
$20,506 | — | 31 Mar 2024 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0.35%
|
4,083
|
$9,799 | — | 31 Mar 2024 | |
| UBS Group AG |
13F
|
Company |
0.06%
|
741
|
$1,778 | — | 31 Mar 2024 | |
| MONTAG A & ASSOCIATES INC |
13F
|
Company |
0.01%
|
141
|
$339 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
50
|
$120 | — | 31 Mar 2024 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
28
|
$67 | — | 31 Mar 2024 | |
| GROUP ONE TRADING LLC |
13F
|
Company |
0%
|
19
|
$45 | — | 31 Mar 2024 | |
| CITIGROUP INC |
13F
|
Company |
0%
|
15
|
$36 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0%
|
14
|
$33 | — | 31 Mar 2024 | |
| NBC SECURITIES, INC. |
13F
|
Company |
0%
|
10
|
$1,000 | — | 31 Mar 2024 | |
| Aspire Private Capital, LLC |
13F
|
Company |
0%
|
10
|
$24 | — | 31 Mar 2024 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0%
|
4
|
$10 | — | 31 Mar 2024 | |
| Freebird Partners LP |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
2,774,627
mixed-class rows
|
$1,503,337 | — | 14 Dec 2023 | |
| George P. Denny III |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
457,442
|
$1,134,456 | — | 02 Dec 2022 | |
| John D. Halpern |
3/4/5
|
10%+ Owner |
—
mixed-class rows
|
1,123,006
mixed-class rows
|
$1,118,891 | — | 02 Dec 2022 | |
| Nicholas J. Singer |
3/4/5
|
Director |
—
mixed-class rows
|
954,608
mixed-class rows
|
$962,330 | — | 02 Dec 2022 | |
| Roger Sidhu |
3/4/5
|
Chief Medical Officer |
—
mixed-class rows
|
80,650
mixed-class rows
|
$200,012 | — | 20 Sep 2022 | |
| Kevin Damour |
3/4/5
|
Chief Scientific Officer |
—
mixed-class rows
|
64,213
mixed-class rows
|
$159,248 | — | 28 Jun 2022 | |
| Andrew C. Jackson |
3/4/5
|
Chief Financial Officer |
—
class O/S missing
|
664,800
|
— | — | 03 Jun 2022 | |
| Howard J. Federoff |
3/4/5
|
CEO & President, Director |
—
class O/S missing
|
413,700
|
— | — | 11 Mar 2022 | |
| Dorothy J. Clarke |
3/4/5
|
General Counsel, Director |
—
class O/S missing
|
168,521
|
— | — | 01 Jan 2024 | |
| Gregory Fiore |
3/4/5
|
Director |
—
class O/S missing
|
165,800
|
— | — | 01 Aug 2022 | |
| Matthew Angel |
3/4/5
|
President and CEO, Director |
—
class O/S missing
|
132,003
|
— | — | 12 Jan 2023 | |
| Jay Sial |
3/4/5
|
Chief Administration Officer |
—
class O/S missing
|
117,200
|
— | — | 11 Mar 2022 | |
| BINDER BRANT |
3/4/5
|
Former director |
—
class O/S missing
|
83,916
|
— | — | 08 Aug 2023 | |
| Richard W. Wagner |
3/4/5
|
Former director |
—
class O/S missing
|
83,916
|
— | — | 08 Aug 2023 | |
| Dennis Langer |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 08 Dec 2021 | |
| Erich Mohr |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 08 Dec 2021 | |
| Erin S. Enright |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 14 Jan 2022 | |
| Heather B. Redman |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 14 Jan 2022 | |
| Luba Greenwood |
3/4/5
|
Director |
—
class O/S missing
|
67,000
|
— | — | 08 Dec 2021 |
Institutional Holders of Ernexa Therapeutics Inc. - Common Stock (ERNA) as of Q2 2024
As of 30 Jun 2024,
Ernexa Therapeutics Inc. - Common Stock (ERNA) was held by
19 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
390,079 shares.
The largest 10 holders included
Cypress Point Wealth Management, LLC, Naviter Wealth, LLC, Sippican Capital Advisors, Corient Private Wealth LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Inc., Avidian Wealth Solutions, LLC, BALDWIN BROTHERS LLC/MA, and Tower Research Capital LLC (TRC).
This page lists
19
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
22
Q2 2024 holders
19
Holder diff
-3
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.